Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) is a life sciences technology company that regularly issues news and updates related to its automated microbial quality control (MQC) solutions for pharmaceutical and biopharmaceutical manufacturing. Company press releases focus on the performance and adoption of its flagship Growth Direct system, which automates and modernizes manual MQC testing workflows used in large and complex pharmaceutical manufacturing operations across the globe.
News for RPID often covers quarterly and annual financial results, including product revenue, service revenue, and recurring revenue from consumables and annual service contracts. The company highlights metrics such as system placements, customer system validations, recurring revenue growth, and record consumable revenue. Updates have also described record multi-system orders from an existing Top 20 global biopharma customer to automate a global manufacturing network across North America, Europe, and Asia Pacific.
Investors and industry followers can also expect announcements about capital structure and financing, such as the disclosed five-year, $45 million term loan facility with Trinity Capital Inc., as well as news on the company’s financial position and outlook. Additional news items include participation in major healthcare and investor conferences, including the J.P. Morgan Healthcare Conference, the Stifel Healthcare Conference, and the H.C. Wainwright Global Investment Conference, where management presents and engages with analysts and investors.
This RPID news page on Stock Titan aggregates these types of updates so readers can quickly review earnings announcements, financing developments, system placement milestones, and conference participation related to Rapid Micro Biosystems. Users interested in the evolution of automated microbial quality control in biopharma manufacturing can monitor this feed for the company’s latest publicly released information.
Rapid Micro Biosystems (Nasdaq: RPID) reported record Q4 2025 revenue of $11.3M (+37% YoY) and full year 2025 revenue of $33.6M (+20% YoY). The company placed 28 Growth Direct systems in 2025 and now has 190 cumulative placements with 155 validated.
Net loss was $47.1M for 2025 and cash plus short-term investments totaled $39.0M. For 2026 the company forecasts revenue of $37.0M–$41.0M, 30–38 system placements, and gross margins of ~20%.
Rapid Micro Biosystems (Nasdaq: RPID) announced a follow-on multi-system order from Samsung Biologics on March 12, 2026 to expand deployment of the Growth Direct platform.
The order strengthens the companies' partnership and supports Samsung's expansion of automated microbial quality control across its manufacturing network, aiming for faster results, greater accuracy, and improved data integrity.
Rapid Micro Biosystems (Nasdaq: RPID) will participate in the KeyBanc Capital Markets Healthcare Forum with a virtual Q&A on March 17, 2026 at 11:15 a.m. ET. A live webcast will be available on the company's investor relations site and will be archived for later replay.
Rapid Micro Biosystems (Nasdaq: RPID) will present at the TD Cowen 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026 at 10:30 a.m. Eastern Time. The presentation will be webcast live and archived for later replay.
According to the company, the live webcast will be available on its investor relations website and accessible for on-demand viewing after the event.
Rapid Micro Biosystems (Nasdaq: RPID) will release fourth quarter and full year 2025 financial results before market open on March 12, 2026.
Management will host a live webcast conference call at 8:30 a.m. ET on March 12, 2026, accessible via the company website; the webcast will be archived for replay after the event.
Rapid Micro Biosystems (Nasdaq: RPID) announced inducement equity awards granted February 2, 2026, to three newly hired employees.
The company granted 205,000 RSUs and 168,000 stock options under its Inducement Plan, with options priced at $4.19 per share and standard time-based vesting schedules.
The awards were approved by a majority of independent directors in accordance with Nasdaq Listing Rule 5635(c)(4).
Rapid Micro Biosystems (Nasdaq: RPID) reported preliminary unaudited revenue results for Q4 and full‑year 2025. Q4 2025 revenue ≈ $11.3M, up ~37% year‑over‑year, including placement of 16 new Growth Direct systems and validation of three customer systems.
Full‑year 2025 revenue is expected to be ≈ $33.6M, up ~20% year‑over‑year, with recurring revenue ≈ $17.8M, up ~15% year‑over‑year. The company placed 28 new Growth Direct systems in 2025 and has cumulatively placed 190 systems with 155 validated.
Results are preliminary and unaudited; final audited results and a webcast with 2026 outlook will be released in Q1 2026. The company will present at the J.P. Morgan Healthcare Conference on Jan 15, 2026.
Rapid Micro Biosystems (Nasdaq: RPID) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026 at 2:15 p.m. ET (11:15 a.m. PT).
A live webcast of the presentation will be available on the company investor relations website and will be archived for replay after the event.
Trinity Capital (Nasdaq: TRIN) announced a $45 million growth capital commitment to Rapid Micro Biosystems (Nasdaq: RPID) to support scaling of the Growth Direct platform and global commercial expansion.
The funding is designated to accelerate manufacturing scale, fund product cost reductions, improve service productivity, and drive gross margin expansion, with the stated goal of strengthening Rapid Micro's financial position and supporting long-term revenue growth and shareholder value.
Rapid Micro Biosystems (Nasdaq: RPID) reported third quarter 2025 results and updated guidance. Q3 revenue was $7.8 million, up 3% year-over-year, with recurring revenue +32% to $4.8 million and record consumable sales. The company posted a Q3 gross margin of 9% and a net loss of $11.5 million (EPS $0.26). Cash, equivalents and short-term investments were about $42 million as of September 30, 2025.
In October, the company received its largest multi-system order from a Top 20 global biopharma to place systems across North America, Europe and Asia Pacific. Rapid Micro raised full-year 2025 revenue guidance to at least $33.0 million, assuming at least 27 Growth Direct placements.